Navigation Links
Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
Date:11/19/2008

HAYWARD, Calif., Nov. 19 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biotechnology company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced that it has closed the final tranche of its Series A financing. Frazier Healthcare Ventures and Alta Partners co-led the $16.7 million tranche, which also included existing investors Burrill & Company, Three Arch Partners, and Altitude Life Science Ventures. This financing completes the Series A round, bringing the total amount raised to date to over $51 million.

"This financing provides substantial funding for Arete as we look toward the initiation of our Phase II clinical trial in the first quarter of 2009 using AR9281 for the treatment of metabolic syndrome," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "We appreciate our investors' continued commitment to the value of our s-EH inhibitor platform."

"In the last six months, Arete successfully completed a Phase I clinical trials' program for AR9281, expanded its executive management team and completed extensive preclinical studies of s-EH inhibitors," stated James Topper, M.D., Ph.D., Chairman of the Board of Arete Therapeutics and General Partner of Frazier Healthcare Ventures. "Arete's extensive proprietary position in s-EH inhibitors, together with its efficient, focused drug discovery and development organization, position the Company to address the growing healthcare epidemic of metabolic syndrome and identify new therapeutics for cardiovascular and inflammatory disease."

About Arete Therapeutics Inc.

Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel drugs to treat metabolic, inflammatory and cardiovascular disease. It is the world's leading company focused on s-EH (soluble epoxide hydrolase), an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company was founded by Dr. Bruce Hammock, a Professor at the University of California, Davis, who discovered s-EH. For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Bolsters Management Team
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
4. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
5. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
9. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
10. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
11. Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
(Date:10/7/2017)... Mass. , Oct. 6, 2017  The ... work of three scientists, Jacques Dubochet, Joachim ... breakthrough developments in cryo-electron microscopy (cryo-EM) ... technology within the structural biology community. The winners ... Scientists can now routinely produce highly resolved, three-dimensional ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):